While more of a longer-term item, in a future post, I will blog about some diligence I did that leads me to believe a potentially major issue will surface as it relates to PV-10 combination therapies.
December 28, 2011
com·bi·na·tion
Dr. Ross concluded his presentation with a slide on combining intralesional therapies. For example, BMS/ipilimumab and Roche/vemurafenib (PLX4032) are being combined.
While more of a longer-term item, in a future post, I will blog about some diligence I did that leads me to believe a potentially major issue will surface as it relates to PV-10 combination therapies.
While more of a longer-term item, in a future post, I will blog about some diligence I did that leads me to believe a potentially major issue will surface as it relates to PV-10 combination therapies.
No comments:
Post a Comment